

Adherium Exhibiting at AAAAI 2023 Annual Meeting

Melbourne, Australia – 13 February 2023: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions will be exhibiting and meeting with commercial partners at the American Association of Allergy, Asthma and Immunology’s 2023 Annual Meeting in San Antonio, Texas on 24-27 February at booth #1369.

Adherium’s Hailie® digital sensors will be featured in the Exhibit Hall of the annual meeting, including recently market released and U.S. FDA 510(k) cleared digital sensors designed for use with the Glaxo Smith Kline’s (GSK) Breo®, Anoro®, Incruse®, Trelegy® and Arnuity® Ellipta dry powder inhalers (DPIs), for monitoring asthma and COPD medication use.

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization in its field. It counts as its members more than 7,000 health professionals in the United States, Canada and 72 other countries. Adherium’s exhibition at the Annual Meeting will be aimed at building additional partnership programs with health system providers and asthma medical groups that serve large groups of US asthma patients.

Over 400 speakers will address thousands of attendees at the AAAAI 2023 Annual Meeting which will have as its theme, “Optimizing Scope of Practice.” The meeting will include a virtual presentation from CDC Director Rochelle Walensky, MD, MPH.

In the last several years remote patient monitoring has emerged as significant area for large asthma clinics to develop new reimbursable monitoring programs to improve medication adherence and outcomes for asthma patients using Adherium’s Hailie sensor technology. By capturing medication usage and physiological parameter data, Adherium’s new series of devices provide a superior perspective into patient adherence and inhaler technique with immediate, real-time feedback thereby allowing patients to improve their quality of life and enabling physicians to enhance patient care.

For more details, please visit: <https://annualmeeting.aaaai.org/>

-ENDS-

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries:
Rick Legleiter
CEO
Adherium Limited
investors@adherium.com